Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

 Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Shots:

  • The approval is based on two P-III studies assessing Taltz vs PBO in 657 patients with active AS, randomized into two groups i.e, COAST-V in patients who are bDMARD-naïve and COAST-W in patients who are intolerant or have an inadequate response to TNF inhibitors
  • The two P-III study results: patients achieved ASAS40 @16wks. COAST-V (48% vs 18%), COAST-W (25% vs 13%); improvement in 2EPs, COAST-V (64% vs 40%), COAST-W (48% vs 30%); reduction in pain & inflammation
  • Taltz is a mAb targeting IL-17A cytokine, inhibiting its interaction with the IL-17 receptor and received its first FDA’s approval in Mar’2016 for mod. to sev. plaque psoriasis and second approval in Dec’2017 for active psoriatic arthritis in adults

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Intex slovakia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post